The ACDIMA Center for Bioequivalence and Pharmaceutical Studies was established in 2000 and is 100% owned by ACDIMA. The center conducts bioavailability and bioequivalence studies, clinical trials, pharmacokinetic studies, pharmaceutical research, and chemical analyses of biological samples. ACDIMA has continuously supported this project in various forms by providing advanced modern equipment and training technical staff. The strategic plan for developing the center has been approved, which includes creating an associated clinical site and enhancing analytical devices to meet global standards in this regard. The center aims to serve as a scientific and technical arm providing scientific support to pharmaceutical manufacturing companies by offering scientific consultations and holding an annual high-level meeting to discuss legislative and regulatory issues governing bioequivalence studies and drug quality. The center has conducted numerous bioequivalence studies for various pharmaceutical formulations for several factories and pharmaceutical companies in Arab and foreign countries, becoming an accredited center by many Arab and international health authorities. It has received accreditation from the World Health Organization (WHO), the Turkish Ministry of Health, and the Malaysian Ministry of Health in recent years, establishing itself as a reference center for these studies. The center is working on implementing its strategic plan to gain further global recognitions by having studies reviewed by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), allowing it to expand into other markets in Europe and America. Currently, it aims to increase the scope of its support activities for the pharmaceutical industry to diversify services and harness all capabilities with exceptional quality and performance. The center has focused its activities on penetrating new markets outside the Arab world and has been evaluated by global European companies for collaboration in conducting studies according to international standards. In 2022, the center achieved a 10% growth in sales and profits amounting to 51,920 Kuwaiti dinars compared to profits of 148,985 Kuwaiti dinars in 2021